Literature DB >> 1451983

Human pancreatic tissue concentration of bactericidal antibiotics.

M Büchler1, P Malfertheiner, H Friess, R Isenmann, E Vanek, H Grimm, P Schlegel, T Friess, H G Beger.   

Abstract

Pancreatic infection represents the most important cause of fatal outcome in human acute pancreatitis. In a comparative analysis, human pancreatic tissue concentrations of 10 different bactericidal antibiotics were determined in 89 patients undergoing pancreatic surgery. Concentrations of the antibiotics were determined in the blood and pancreatic tissue using high-pressure liquid chromatography. Pancreatic tissue concentrations 120 minutes after intravenous administration were as follows: mezlocillin, 19.0 mg/kg; piperacillin, 20.3 mg/kg; cefotaxime, 9.1 mg/kg; ceftizoxime, 7.9 mg/kg; netilmicin, 0.4 mg/kg; tobramycin, 0.4 mg/kg; ofloxacin, 1.7 mg/kg; ciprofloxacin, 0.9 mg/kg; imipenem, 6.0 mg/kg; metronidazole, 3.5 mg/kg. Three groups of antibiotics were established: group A, substances with low tissue concentrations (netilmicin, tobramycin), which were below the minimal inhibitory concentrations of most bacteria found in pancreatic infection; group B, antibiotics with pancreatic tissue concentrations which were sufficient to inhibit some but not all bacteria in pancreatic infection (mezlocillin, piperacillin, ceftizoxime, cefotaxime); group C, substances with high pancreatic tissue levels as well as high bactericidal activity against most of the germs present in pancreatic infection (ciprofloxacin, ofloxacin, imipenem). These data could serve as the basis for adequate antibiotic prophylaxis or treatment of pancreatic infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451983     DOI: 10.1016/0016-5085(92)91450-i

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  46 in total

Review 1.  Prophylactic antibiotics and pancreatic necrosis.

Authors:  B Gloor; O Schmidt; W Uhl; M W Büchler
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 2.  The role of infection in acute pancreatitis.

Authors:  S W Schmid; W Uhl; H Friess; P Malfertheiner; M W Büchler
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

3.  Pancreatic necrosis: to debride or not to debride-that is the question.

Authors:  A L Warshaw
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

Review 4.  Current management of acute pancreatitis.

Authors:  Thomas E Clancy; Eric P Benoit; Stanley W Ashley
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

5.  Piperacillin-tazobactam penetration into human pancreatic juice.

Authors:  Elisa Bertazzoni Minelli; Anna Benini; Luigina Franco; Claudio Bassi; Paolo Pederzoli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

Review 6.  Early management of severe acute pancreatitis.

Authors:  Rupjyoti Talukdar; Santhi Swaroop Vege
Journal:  Curr Gastroenterol Rep       Date:  2011-04

7.  The use of antibiotics for acute pancreatitis: is there a role?

Authors:  Hans G Beger; Frank Gansauge; Bertram Poch; Michael Schwarz
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

8.  Behavior of antibiotics during human necrotizing pancreatitis.

Authors:  C Bassi; P Pederzoli; S Vesentini; M Falconi; A Bonora; H Abbas; A Benini; E M Bertazzoni
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Early antibiotic treatment (prophylaxis) of septic complications in severe acute necrotizing pancreatitis: a prospective, randomized, multicenter study comparing two regimens with imipenem-cilastatin.

Authors:  Enrique Maraví-Poma; Joan Gener; Francisco Alvarez-Lerma; Pedro Olaechea; Armando Blanco; J Enrique Domínguez-Muñoz
Journal:  Intensive Care Med       Date:  2003-10-10       Impact factor: 17.440

Review 10.  Antibiotic prophylaxis of pancreatic infection in patients with necrotizing pancreatitis: rationale, evidence, and recommendations.

Authors:  Issac Moyshenyat; Ephraim Mandell; Scott Tenner
Journal:  Curr Gastroenterol Rep       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.